CERU CERULEAN PHARMA

Daré Bioscience to Present at the 2020 BIO Investor Forum Digital

Daré Bioscience to Present at the 2020 BIO Investor Forum Digital
EN
07/10/2020

Underlying

CERUCERULEAN PHARMA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CERULEAN PHARMA

 PRESS RELEASE
Free
CERU CERULEAN PHARMA

Daré Bioscience Announces Common Stock Purchase Agreement for up to $1...

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC Provides Daré access to capital at Daré’s discretion with any proceeds available to help fund portfolio advancement, such as the Phase 3 program for Sildenafil Cream, 3.6%, a potential first-in-category treatment for female sexual arousal disorder using the same active ingredient as in Viagra® SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today announced it entered into a $1...

October 21, 2024 1 EN
 PRESS RELEASE
Free
CERU CERULEAN PHARMA

Daré Bioscience Announces Publication in The Journal of Sexual Medicin...

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% Published data show that topical Sildenafil Cream, 3.6% was safe and well tolerated by women and their partners across 1,357 sexual experiences. Use of topical Sildenafil Cream, 3.6% did not produce the common side effects of headache and flushing associated with oral sildenafil use in women. SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and we...

August 26, 2024 1 EN
 PRESS RELEASE
Free
CERU CERULEAN PHARMA

Daré Bioscience Announces Publication in The Journal of Sexual Medicin...

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies Longer recall intervals for PRO assessments are less burdensome to clinical study participants and may improve data collection compliance SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NA...

August 13, 2024 1 EN
 PRESS RELEASE
Free
CERU CERULEAN PHARMA

Daré Bioscience Reports Second Quarter 2024 Financial Results and Prov...

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United StatesSildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder continued operational progress toward a planned Phase 3 study; additional FDA feedback forthcoming; Phase 3 design, development, an...

August 12, 2024 1 EN
 PRESS RELEASE
Free
CERU CERULEAN PHARMA

Daré Bioscience to Host Second Quarter 2024 Financial Results and Comp...

Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024 SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, August 12, 2024, to review its financial results for the quarter ended June 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Monday, August 12, 2024, and prior to the con...

August 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch